B. Lagu

发表

Identification of alpha1A-adrenoceptor selective antagonists for the treatment of benign prostatic hyperplasia

B. Lagu, 2001 .

beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.

K. Rhodes, B. Lagu, R. Scannevin, 2008, Bioorganic & medicinal chemistry letters.

β-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: Part 2. Optimization of α-amino substituents

K. Rhodes, B. Lagu, R. Scannevin, 2008 .

Addressing hERG activity while maintaining favorable potency, selectivity and pharmacokinetic properties of PPARδ modulators.

B. Lagu, M. Patane, A. Kluge, 2019, Bioorganic & medicinal chemistry letters.

Synthesis of sterically hindered enamides via a Ti-mediated condensation of amides with aldehydes and ketones.

B. Lagu, Julien Genovino, Yaping Wang, 2012, Chemical communications.

In vitro studies on L-771,688 (SNAP 6383), a new potent and selective alpha1A-adrenoceptor antagonist.

M. Bock, R. Chang, B. Lagu, 2000, European journal of pharmacology.

Discovery of NVP‐LEQ506, a Second‐Generation Inhibitor of Smoothened

John Green, J. Williams, B. Lagu, 2013, ChemMedChem.

Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy.

B. Lagu, J. Malhotra, James E. Thompson, 2018, Bioorganic & medicinal chemistry letters.

Potent and selective CC-chemokine receptor-2 (CCR2) antagonists as a potential treatment for asthma.

B. Lagu, M. Singer, R. Malaviya, 2007, Bioorganic & medicinal chemistry letters.

RXR-LXR heterodimer modulators for the potential treatment of dyslipidemia.

B. Lagu, B. Pio, Maria X. Yang, 2007, Bioorganic & medicinal chemistry letters.

Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD).

M. Goddeeris, Sunil K. Panigrahi, B. Lagu, 2018, ACS medicinal chemistry letters.

Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.

M. Goddeeris, B. Lagu, E. Tozzo, 2017, Bioorganic & medicinal chemistry letters.

Novel highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulators with pharmacokinetic properties suitable for once-daily oral dosing.

Sunil K. Panigrahi, B. Lagu, E. Tozzo, 2017, Bioorganic & medicinal chemistry letters.

From Ergolines to Indoles: Improved Inhibitors of the Human H3 Receptor for the Treatment of Narcolepsy

M. Bock, Y. Auberson, Charles R. Yang, 2015, ChemMedChem.

Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 1. Structure-activity relationship in dihydropyrimidinones.

R. Chang, P. Kling, B. Lagu, 1999, Journal of medicinal chemistry.

Aldol reactions of α-(N,N-dibenzylamino) ethyl ketones

B. Lagu, D. Liotta, J. Goh, 1994 .

Synthesis and evaluation of furo[3,4-d]pyrimidinones as selective alpha1a-adrenergic receptor antagonists.

R. Chang, B. Lagu, C. Forray, 2000, Bioorganic & medicinal chemistry letters.

3-alkoxy-pyrrolo[1,2-b]pyrazolines as selective androgen receptor modulators with ideal physicochemical properties for transdermal administration.

M. Bock, B. Lagu, M. Ramachandra, 2014, Journal of medicinal chemistry.

3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists.

T. Blackburn, B. Lagu, H. Akunne, 2006, Journal of medicinal chemistry.

A Versatile Synthesis of Polysubstituted Pyrroles

B. Lagu, Meng Pan, P. WachterMichael, 2001 .

Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 4. Structure-activity relationship in the dihydropyrimidine series.

R. Chang, P. Kling, B. Lagu, 1999, Journal of medicinal chemistry.

Surprisingly high diastereoselection in the aldol reactions of sodium enolates of α-amino methyl ketones

B. Lagu, D. Liotta, 1994 .

Two diastereomers of 2-[[β-(N-phenylamino)-α-methylphenethyl]-methylamino]-N,N-dimethylacetamide

N. Deo, B. Lagu, W. Pennington, 1997 .

De novo design of a novel oxazolidinone analogue as a potent and selective alpha1A adrenergic receptor antagonist with high oral bioavailability.

A. D. Rodrigues, R. Chang, B. Lagu, 2000, Journal of medicinal chemistry.

Stereo- and regioselective synthesis of chiral diamines and triamines from pseudoephedrine and ephedrine

N. Deo, B. Lagu, R. Dieter, 1992 .

NMR studies of (amido)cuprates

B. Lagu, T. Hanks, R. Dieter, 1992 .

Diastereoselective synthesis of the key lactone intermediate for the preparation of hydroxyethylene dipeptide isosteres

B. Lagu, D. Liotta, 1994 .

A method for estimating the risk of drug-induced phototoxicity and its application to smoothened inhibitors

William Egan, W. Egan, B. Lagu, 2011 .

Ergoline‐Derived Inverse Agonists of the Human H3 Receptor for the Treatment of Narcolepsy

M. Fendt, M. Bock, Y. Auberson, 2014, ChemMedChem.

Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors.

Paul N. Mortenson, M. Congreve, R. Cheng, 2012, ACS medicinal chemistry letters.

Stereoselectivity of induction of the retinoblastoma gene product (pRb) dephosphorylation by D-erythro-sphingosine supports a role for pRb in growth suppression by sphingosine.

A. Bielawska, Y. Hannun, B. Lagu, 1995, Biochemistry.

Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor.

D. Chin, B. Lagu, B. Firestone, 2013, Journal of medicinal chemistry.

Mild and efficient Lewis acid-promoted detritylation in the synthesis of N-hydroxy amides: a concise synthesis of (-)-Cobactin T.

B. Lagu, L. Wilson, Shyh-Ming Yang, 2007, The Journal of organic chemistry.

Synthesis and Evaluation of Furo[3,4-d]pyrimidinones as Selective α1a-Adrenergic Receptor Antagonists.

B. Lagu, 2000 .

beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.

K. Rhodes, B. Lagu, R. Scannevin, 2008, Bioorganic & medicinal chemistry letters.

Dihydro-[1H]-quinolin-2-ones as retinoid X receptor (RXR) agonists for potential treatment of dyslipidemia.

B. Lagu, B. Pio, Maria X. Yang, 2007, Bioorganic & medicinal chemistry letters.

Discovery of Potent Allosteric DRP1 Inhibitors by Disrupting Protein–Protein Interaction with MiD49

B. Lagu, L. Molz, T. Furuya, 2023, ACS Medicinal Chemistry Letters.

The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders

M. Bock, Y. Auberson, Charles R. Yang, 2019, ChemMedChem.

Orally Bioavailable Enzymatic Inhibitor of CD38, MK-0159, Protects against Ischemia/Reperfusion Injury in the Murine Heart.

B. Lagu, A. Papapetropoulos, Rakesh Paul, 2022, Journal of medicinal chemistry.

Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD).

M. Goddeeris, Sunil K. Panigrahi, B. Lagu, 2018, ACS medicinal chemistry letters.